These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 14720038)

  • 21. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
    Gauvreau GM; Arm JP; Boulet LP; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Killian KJ; Laviolette M; Carlsten C; Lazarinis N; Watson RM; Milot J; Swystun V; Bowen M; Hui L; Lantz AS; Meiser K; Maahs S; Lowe PJ; Skerjanec A; Drollmann A; O'Byrne PM
    J Allergy Clin Immunol; 2016 Oct; 138(4):1051-1059. PubMed ID: 27185571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-immunoglobulin E, a monoclonal antibody to treat respiratory disorders].
    Cabrera-Navarro P
    Arch Bronconeumol; 2006 May; 42(5):241-5. PubMed ID: 16740240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-IgE therapy in asthma: rationale and therapeutic potential.
    Barnes PJ
    Int Arch Allergy Immunol; 2000 Nov; 123(3):196-204. PubMed ID: 11112855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.
    D'Amato G; Oldani V; Donner CF
    Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab in allergic diseases, a recent review.
    Vichyanond P
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of action of anti-immunoglobulin E therapy.
    Soresi S; Togias A
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S15-23. PubMed ID: 16722327
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Kowal K; Bielecki P; DuBuske IV; DuBuske LM
    Allergy Asthma Proc; 2017 May; 38(3):204-215. PubMed ID: 28441991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
    Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-IgE as a mast cell-stabilizing therapeutic agent.
    Chang TW; Shiung YY
    J Allergy Clin Immunol; 2006 Jun; 117(6):1203-12; quiz 1213. PubMed ID: 16750976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
    Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
    J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IgE as novel therapy for the treatment of asthma.
    Fick RB
    Curr Opin Pulm Med; 1999 Jan; 5(1):76-80. PubMed ID: 10813254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of allergic diseases with monoclonal anti-IgE antibody].
    Morita Y
    Nihon Rinsho; 2001 Oct; 59(10):2019-22. PubMed ID: 11676148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody.
    D'Amato G
    Expert Opin Biol Ther; 2003 Apr; 3(2):371-6. PubMed ID: 12662149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omalizumab, a novel anti-IgE therapy in allergic disorders.
    Babu KS; Arshad SH; Holgate ST
    Expert Opin Biol Ther; 2001 Nov; 1(6):1049-58. PubMed ID: 11728235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
    Cohen ES; Dobson CL; Käck H; Wang B; Sims DA; Lloyd CO; England E; Rees DG; Guo H; Karagiannis SN; O'Brien S; Persdotter S; Ekdahl H; Butler R; Keyes F; Oakley S; Carlsson M; Briend E; Wilkinson T; Anderson IK; Monk PD; von Wachenfeldt K; Eriksson PO; Gould HJ; Vaughan TJ; May RD
    MAbs; 2014; 6(3):756-64. PubMed ID: 24583620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attainments in atop: special aspects of allergy and IgE.
    Milgrom H
    Adv Pediatr; 2002; 49():273-97. PubMed ID: 12214775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.